Psychedelic use and psychiatric risks
In a US-representative sample (N=2,822), lifetime naturalistic psychedelic use was associated with more lifetime unusual visual experiences and a 1.3% self-reported rate of hallucinogen persisting perception disorder, but not with greater past-two-week psychotic symptoms overall. There was an interaction with family history: psychedelic users with a family history of psychotic or bipolar disorders reported higher recent psychotic symptoms, whereas users without such a family history reported lower symptoms.
Authors
- Otto Simonsson
- Peter Hendricks
- Wojciech Osika
Published
Abstract
Rationale
Research on psychedelics has recently shown promising results in the treatment of various psychiatric disorders, but relatively little remains known about the psychiatric risks associated with naturalistic use of psychedelics.
Objective
The objective of the current study was to investigate associations between naturalistic psychedelic use and psychiatric risks.
Methods
Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N=2822), this study investigated associations between lifetime naturalistic psychedelic use, lifetime unusual visual experiences, and past 2-week psychotic symptoms.
Results
Among respondents who reported lifetime psychedelic use (n=613), 1.3% reported having been told by a doctor or other medical professional that they had hallucinogen persisting perception disorder. In covariate-adjusted linear regression models, lifetime psychedelic use was associated with more unusual visual experiences at any point across the lifetime, but no association was observed between lifetime psychedelic use and past 2-week psychotic symptoms. There was an interaction between lifetime psychedelic use and family (but not personal) history of psychotic or bipolar disorders on past 2-week psychotic symptoms such that psychotic symptoms were highest among respondents who reported lifetime psychedelic use and a family history of psychotic or bipolar disorders and lowest among those who reported lifetime psychedelic use and no family history of psychotic or bipolar disorders.
Conclusions
Although the results in this study should be interpreted with caution, the findings suggest that lifetime naturalistic use of psychedelics might be associated with more unusual visual experiences across the lifetime, as well as more psychotic symptoms in the past 2 weeks for individuals with a family history of psychotic or bipolar disorders and the reverse for those without such a family history. Future research should distinguish between different psychotic and bipolar disorders and should also utilize other research designs (e.g., longitudinal) and variables (e.g., polygenic risk scores) to better understand potential cause-and-effect relationships.
Research Summary of 'Psychedelic use and psychiatric risks'
Introduction
Earlier research has shown therapeutic promise for psychedelics in treating several psychiatric disorders, but the safety evidence comes mostly from clinical trials that apply strict exclusion criteria. As a result, relatively little is known about psychiatric risks associated with naturalistic (non‑clinical) psychedelic use, particularly among groups typically excluded from trials such as people with personal or family histories of psychotic or bipolar disorders. Potential risks discussed in the literature include persistent visual phenomena (hallucinogen persisting perception disorder, HPPD) and, more rarely, onset or exacerbation of psychosis or mania, but prevalence estimates and predictors remain uncertain and prior epidemiological findings are mixed. Simonsson and colleagues set out to examine associations between lifetime naturalistic psychedelic use, unusual visual experiences, and recent psychotic symptoms in a sample intended to be representative of the US adult population by sex, age, and ethnicity. The aim was to assess whether lifetime psychedelic use relates to lifetime unusual visual phenomena and to psychotic symptoms in the past 2 weeks, and to test whether personal or family histories of psychotic or bipolar disorders modify these associations.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Topics
- Authors
- APA Citation
Simonsson, O., Goldberg, S. B., Chambers, R., Osika, W., Simonsson, C., & Hendricks, P. S. (2025). Psychedelic use and psychiatric risks. Psychopharmacology, 242(7), 1577-1583. https://doi.org/10.1007/s00213-023-06478-5
References (14)
Papers cited by this study that are also in Blossom
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Baggott, M. J., Coyle, J. R., Erowid, E. et al. · Drug and Alcohol Dependence (2011)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Galvão-Coelho, N. L., Marx, W., Sinclair, J. et al. · Psychopharmacology (2021)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Halpern, J. H., Pope Jr, H. G. · Drug and Alcohol Dependence (2003)
Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)
Krebs, T. S., Johansen, P. ˚. Ø. · PLOS ONE (2013)
Lebedev, A. V., Acar, K., Garzón, B. et al. · Scientific Reports (2021)
Müller, F., Holze, F., Becker, A. M. et al. · Psychopharmacology (2022)
Show all 14 referencesShow fewer
Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)
Simonsson, O., Sexton, J. D., Hendricks, P. S. · Journal of Psychopharmacology (2021)
Strassman, R. J. · Journal of Nervous and Mental Disease (1984)
Schindowski, E. M., Jungwirth, J., Schuldt, A. et al. · EClinicalMedicine (2023)
Cited By (3)
Papers in Blossom that reference this study
Dourron, H. M., Bradley, M. K., Copes, H. et al. · International Journal of Mental Health and Addiction (2026)
Bradley, E. R., Sakai, K., Fernandes-Osterhold, G. et al. · Neuropsychopharmacology (2025)
Argyri, E. K., Evans, J., Luke, D. et al. · SSRN (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.